Momelotinib

Momelotinib

Another Name
OJJAARA、Omjjara、LuciMomel、莫洛替尼
Indications
Momelotinib is indicated for the treatment of intermediate or high-risk myelofibrosis.
Reg No
06 L 1113/24
Inspection No
1074-24
dosage form:tablet
Specs:100mg*30 tablets
Indate:24 months
Date：2024-9-1 Views：1170
Drug Info

COMPOSITION:

Eachfilm-coated tablet contains Momelotinib dihydrochloride monohydrate 121.94 mg equivalent to Momelotinib…….100 mg.

INDICATION:

LuciMomel is a kinase inhibitor indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.

DOSAGE AND USE:

• Recommended dosage: 200 mg orally once daily.

• Severe hepatic impairment (Child-Pugh Class C): Reduce the starting dose to 150 mg orally once daily. Swallow tablets whole with or without food.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciMomel during Pregnancy and Lactation.

Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/momelotinib/

Related News